LEADERSHIP BEYOND QUESTION
Abbott’s leadership in congenital occluder therapies is due to the Amplatzer product line’s 20-year history of established therapies—and due to our dedication to continual innovation. Each year 1.35 million infants are born, worldwide, with congenital heart disease.1 Abbott has a broad portfolio of products to correct structural heart defects, as well as a devoted focus on patient safety. Consequently, we concentrate on enhancing ease of use and expanding clinical safety data for our products.
PIONEER IN PFO OCCLUSION
Because the Amplatzer line pioneered the patent foramen ovale (PFO)-specific occlusion device, it’s no surprise that the Amplatzer PFO Occluder is the leading PFO closure device.2